DENVER, Colo. (247marketnews.com) -- PDS Biotech (NASDAQ:PDSB) is entering a potentially pivotal stretch with fresh capital, a high-profile new board member and a sharply narrowed clinical strategy centered on its PDS0301 immunocytokine.
The company continues to push since Monday’s announcement that it completed the initial closing of a PIPE financing that generated approximately $11.3 million in gross proceeds, with Nant Capital leading the transaction. The broader financing can reach approximately $22.3 million, with another $11 million contingent on a key development milestone tied to submission of a registrational Phase 3 protocol for PDS0301 to the FDA.
The financing comes with an unusually prominent biotech name attached: Dr. Patrick Soon-Shiong, founder of NantWorks, has joined PDS Biotech's board of directors. Soon-Shiong said the company is developing “promising novel cancer vaccines and immunocytokines” and that he was pleased to join the board and contribute to advancing the therapies.
For PDSB, however, the money may matter more than the headline name, since it’s refocusing its resources around PDS0301, a tumor-targeted IL-12 immunocytokine designed to concentrate immune-stimulating activity in the tumor microenvironment. PDS Biotech says the program is being positioned for late-stage development after encouraging Phase 2 data in metastatic microsatellite-stable and mismatch-repair-proficient colorectal cancer, forms of the disease where immunotherapy has historically faced significant resistance.
The clinical numbers are driving the renewed attention. In an NCI-led Phase 2 study, PDS Biotech has reported that 80% of 22 patients survived at least 24 months, while the company has separately highlighted a 71% objective response rate at six months in patients with metastatic MSS/pMMR colorectal cancer and liver metastases. These are interim clinical findings from a relatively small patient population and will need confirmation in later-stage testing.
Under the transaction structure, Nant and AB Group are obligated to provide an additional $11 million collectively when the specified Phase 3 protocol submission milestone is reached, subject to closing conditions. The company says the capital is intended to support clinical development, research and development, working capital and other corporate expenses.
PDSB is also simplifying its broader portfolio. In August, the company announced that it would stop further internal investment in PDS0101 and discontinue the VERSATILE-003 Phase 3 trial, while pursuing partnerships or other external funding for future development of the HPV-targeted program. The strategic refocus puts considerably more attention, and capital, behind PDS0301.
There is another potential catalyst buried in the transaction: NantWorks received a one-year exclusive right to negotiate an exclusive license for PDS0101. That creates a possible partnership path for the program without requiring PDS Biotech to fund it entirely from its own balance sheet.
CEO Frank Bedu-Addo said the company believes the NCI data “strongly suggest that PDS0301 has the potential to advance the treatment of solid tumors with immunotherapy.”
The next phase of the story is therefore unusually straightforward: convert promising Phase 2 evidence into a registrational development plan, reach the milestone financing, and determine whether PDS0301 can reproduce its early signal in a larger trial.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.